Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
Sponsor: University of California, Davis
Summary
Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2014-12
Completion Date
2026-07
Last Updated
2025-12-05
Healthy Volunteers
No
Conditions
Interventions
Pneumovax-23
Locations (1)
University of California, Davis Medical Center
Sacramento, California, United States